This site is intended for healthcare professionals
CDK4/6 inhibitor selection in metastatic breast cancer

Welcome

Read time: 125 mins
Published:30th May 2020
Are you familiar with the clinical trial evidence that could help you to select the best cyclin dependent kinase 4/6 (CDK4/6) inhibitor for your metastatic breast cancer patient?

Abemaciclib, palbociclib and ribociclib are three EMA and FDA approved CDK4/6 inhibitors for the treatment of hormone receptor positive/human epidermal growth factor 2 negative (HR+/HER2-) metastatic breast cancer1–6. This learning zone aims to introduce the clinical trial data that will help you to select the best CDK4/6 inhibitor for your patient. We highlight how differences in safety and toxicity between the three treatments may influence your decision. We also discuss the evidence for each inhibitor in distinct patient subgroups including postmenopausal women, premenopausal women and the elderly.

We also point out how the data differ for each CDK4/6 inhibitor according to disease characteristics including endocrine sensitivity, type of metastasis, central nervous system involvement, and pretreatment.

Register free for full access to medthority.com

This content has been developed independently of the sponsor, Lilly, which has had no editorial input into the content. Medthority received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.